Key result
Red yeast rice is linked to ~64% lower ESRD risk versus lovastatin in hyperlipidemia.
Why the study?
The potential relationship between red yeast rice (RYR) consumption and the development of end-stage renal disease (ESRD) remains poorly understood.
Does receiving physician-prescribed red yeast rice (LipoCol Forte) reduce or increase the risk of incident end-stage renal disease compared to lovastatin in adults with hyperlipidemia?
Cohort (n=158,712)
Yes
Does receiving physician-prescribed red yeast rice (LipoCol Forte) reduce or increase the risk of incident end-stage renal disease compared to lovastatin in adults with hyperlipidemia?
Answers are grounded in this paper and cite their sources.
In a large Taiwanese nationwide cohort, prescription medical-grade red yeast rice (LipoCol Forte) was associated with a significantly lower risk of progressing to end-stage renal disease compared to lovastatin and other statins.
Background The potential relationship between the consumption of red yeast rice (RYR) and the development of end-stage renal disease (ESRD) remains poorly understood. We aimed to evaluate the risk of ESRD in patients who used RYR. Methods Utilizing insurance claim records from 2010 to 2014, we performed a retrospective cohort analysis comparing 67,876 individuals using RYR against a control group of 90,836 lovastatin users (non-RYR group) , with follow-up extending through 2019. The incidence of ESRD was analyzed using adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) within Cox proportional hazard models. Results During follow-up, the ESRD incidence was 0.9 per 1,000 person-years in RYR users, compared to 3.7 per 1,000 person-years in lovastatin users (HR 0.36, 95% CI 0.32–0.40). A dose-dependent reduction in ESRD risk was observed with increasing RYR prescriptions. Sensitivity analysis, excluding ESRD cases within the initial six months, confirmed a persistent association between RYR use and reduced ESRD risk (adjusted HR 0.72, 95% CI 0.64–0.81). Conclusion RYR intake may be linked to a decreased likelihood of progressing to ESRD. Despite these promising results, factors such as medication adherence necessitate cautious interpretation. Further randomized controlled trials are required to validate these findings and clarify RYR’s role in slowing kidney disease progression.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) conducted a cohort in Hyperlipidemia (n=158,712). Physician-prescribed medical-grade red yeast rice (LipoCol Forte, containing 600 mg of Monascus purpureus Went rice and 5.7 mg of lovastatin per capsule) vs. Lovastatin users without red yeast rice intake (non-RYR group) was evaluated on Incidence of end-stage renal disease (ESRD) requiring chronic renal replacement therapy (peritoneal dialysis or hemodialysis) (HR 0.36, 95% CI 0.32-0.40, p=<0.0001). Red yeast rice prescriptions were associated with a lower incidence of end-stage renal disease compared to lovastatin in patients with hyperlipidemia.
Synapse has enriched 10 related papers. Consider them for comparative context: